The Axial Spondyloarthritis (axSpA) Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions - Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).
Learn More On The Axial Spondyloarthritis (axSpA) Market:
https://www.thebusinessresearchcompany.com/report/axial-spondyloarthritis-axspa-global-market-report
According to The Business Research Company’s Axial Spondyloarthritis (axSpA) Global Market Report 2024, The axial spondyloarthritis (axspa) market size has grown strongly in recent years. It will grow from $5.54 billion in 2023 to $6.04 billion in 2024 at a compound annual growth rate (CAGR) of 9.0%. The growth in the historic period can be attributed to improved diagnostic criteria, biological treatment advancements, rising disease awareness, genetic research advances, clinical trial progress.
The axial spondyloarthritis (axspa) market size is expected to see strong growth in the next few years. It will grow to $8.18 billion in 2028 at a compound annual growth rate (CAGR) of 7.9%. The growth in the forecast period can be attributed to advancements in biomarker identification, tailored therapies, digital health integration, expanded treatment options, healthcare policy support. Major trends in the forecast period include early intervention strategies, patient-centric care, telemedicine and remote consultations, research on disease mechanisms, shared decision-making.
The increasing prevalence of spondyloarthritis is expected to propel the growth of the axial spondyloarthritis (axSpa) market going forward. Spondyloarthritis is a chronic illness that typically affects the axial skeleton, including the spine and sacroiliac joints. The rising cases of spondyloarthritis (axSpA) can be associated with the increasing aging population and spine injuries from even minor falls or other accidents, where various treatments are provided for pain management, inflammation control, and enhancing the patient's quality of life suffering from axSpA. For instance, in June 2023, according to Versus Arthritis's Musculoskeletal Health Report 2023, a UK-based charity dedicated to supporting people with arthritis, as of the year 2022, around 60,000 individuals were afflicted with axial spondyloarthritis, and annually, approximately 2,200 adults receive a new diagnosis for this condition. Therefore, the increasing prevalence of axial spondyloarthritis (axSpa) is driving the growth of the axial spondyloarthritis (axSpa) market.
Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=12590&type=smp
The axial spondyloarthritis (axspa) market covered in this report is segmented –
1) By Types: Ankylosing spondylitis (AS), Non-radiographic axial spondyloarthritis (nr-axSpA)
2) By Commercialized Therapies: Anti-tumor Necrosis Factor Therapy (TNF), Anti-Interleukin Therapy (IL), Anti-Janus Kinase Therapy (JAK)
3) By Dosage Form: Tablets, Injections
4) By Treatment: Tumor necrosis factor (TNF) Alpha Inhibitors, Non-steroidal anti-inflammatory drugs (NSAID), Conventional Disease Modifying Anti-Rheumatic Drugs, Glucocorticoids, Interleukin Blockers
5) By End-Use: Hospital Pharmacies, Retailer Pharmacies, Online Pharmacy Stores
Product innovations are the key trend gaining popularity in the axial spondyloarthritis (axSpA) market. Major companies operating in the axial spondyloarthritis (axSpA) market are developing new drugs to sustain their position in the market. For instance, in June 2023, UCB SA, a Belgium-based pharmaceutical company, received approval from the New European Commission for the marketing authorization of BIMZELX (bimekizumab). This medication is used to treat adults with active axial spondyloarthritis (axSpA), non-radiographic axial spondyloarthritis (nr-axSpA), and ankylosing spondylitis (AS) with objective signs of inflammation as indicated by elevated C-reactive protein. These European Union (EU) authorizations represent the drug's first global marketing licenses for axial spondyloarthritis.
The axial spondyloarthritis (axspa) market report table of contents includes:
1. Executive Summary
2. Axial Spondyloarthritis (axSpA) Market Characteristics
3. Axial Spondyloarthritis (axSpA) Market Trends And Strategies
4. Axial Spondyloarthritis (axSpA) Market - Macro Economic Scenario
5. Global Axial Spondyloarthritis (axSpA) Market Size and Growth
.....................
31. Axial Spondyloarthritis (axSpA) Market Other Major And Innovative Companies
32. Global Axial Spondyloarthritis (axSpA) Market Competitive Benchmarking
33. Global Axial Spondyloarthritis (axSpA) Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Axial Spondyloarthritis (axSpA) Market
35. Axial Spondyloarthritis (axSpA) Market Future Outlook and Potential Analysis
Read Related Topics:
https://goodprnews.com/wagyu-beef-global-market-size/
https://goodprnews.com/wedding-service-global-market-size/
https://goodprnews.com/wooden-interior-door-global-market-size/
https://topprnews.com/wagyu-beef-global-market-share/
https://topprnews.com/wedding-service-global-market-share/
https://topprnews.com/wooden-interior-door-global-market-share/
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Non-radiographic axial spondyloarthritis market is a type of inflammatory arthritis, a hetrogenous group of autoimmune disorders that causes pain in lower back.
The non-radiographic means that the symptoms or inflammation will not visible on x-ray (radiograph) but can show on MRI (magnetic resonance imaging) scan however it can negative too and axial spondyloarthritis means arthritis affect mainly on the spine.
The patients with non- radiographic axial spondyloarthritis experience the severe back pain.According to the statistics puplished in the UCB S.A., an estimated adult population of non-radiographic axial spondyloarthritis is up to 0.5% to 1.4%.
Growing incidence of non-radiographic axial spondyloarthritis, accelerating demand of novel therapies and treatment are the key drivers for market growthThis Non-Radiographic Axial Spondyloarthritis Therapeutics Market research report intensely analyses the potential of the market with respect to current scenario and the future prospects by considering several industry aspects of Cardinal Health industry.
The report also recognizes and analyses the rising trends along with major drivers, challenges and opportunities in the market.
This Non-Radiographic Axial Spondyloarthritis Therapeutics Market report provides major statistics on the market status of global and regional manufacturers and is a helpful source of assistance and direction for companies and individuals interested in Healthcare industry.
Non-Radiographic Axial Spondyloarthritis Therapeutics Market is a type of inflammatory arthritis, a hetrogenous group of autoimmune disorders that causes pain in lower back.
The non-radiographic means that the symptoms or inflammation will not visible on x-ray (radiograph) but can show on MRI (magnetic resonance imaging) scan however it can negative too and axial spondyloarthritis means arthritis affect mainly on the spine.
The patients with non- radiographic axial spondyloarthritis experience the severe back pain.Global non-radiographic axial spondyloarthritis therapeutics market is rising gradually registering a substantial in the forecast period of 2019-2026.
The report contains data of the base year 2018 and historic year 2017.
The emergence of drugs used in the treatment of celiac disease, inflammatory bowel disease, hyperthyroidism, chronic obstructive pulmonary disease (COPD) and bone marrow cancer, growing aging population are the key drivers for market growth.
Get Sample Report at : https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-non-radiographic-axial-spondyloarthritis-therapeutics-marketCompetitive Analysis: Global Non-Radiographic Axial Spondyloarthritis Therapeutics MarketFew of the major competitors currently working in Global Non-Radiographic Axial Spondyloarthritis Therapeutics Market are Allergan, Amgen Inc, Astellas Pharma Inc, AstraZeneca, Daiichi Sankyo Company, Limited, Eli Lilly and Company, Teijin Pharma Limited, Stelis Biopharma, Radius Health, Inc, Pfizer Inc, Ono Pharmaceutical Co., Ltd, Novartis AG, Mochida Pharmaceutical Co., Ltd, Mereo BioPharma Group plc, Merck & Co., Inc, Gedeon Richter (UK) Ltd, F. Hoffmann-La Roche Ltd, Novo Nordisk A/S, Cipla Inc, UCB SA, Teva Pharmaceutical Industries Ltd and among others.
